Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

(2012) James Mu et al.   PLoS One

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice

(2011) Y. Lee et al.   DIABETES

Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models

(2011) P. M. Vuguin et al.   DIABETES OBESITY & METABOLISM

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

(2011) J. Mu et al.   DIABETOLOGIA

Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?

(2011) N M Whalley et al.   JOURNAL OF ENDOCRINOLOGY

Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible  -Cell Hyperplasia and Hyperglucagonemia

(2009) W. Gu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, α Cell Hyperplasia, and Islet Cell Tumor

(2009) Cuiqi Zhou et al.   PANCREAS

The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

(2008) Christine Longuet et al.   Cell Metabolism